

# KEYPAD Trial News

[www.anzup.org.au](http://www.anzup.org.au)

## Welcome to the first KEYPAD study newsletter for 2021

Thank you to all the KEYPAD investigators and trial teams for your continued efforts with the KEYPAD study. We have just 26 patients to recruit to reach our target.

I am also pleased to share with you the [KEYPAD Trial in Progress Poster](#) which featured at the ASCO GU 2021 Virtual Meeting.

*A/Professor Craig Gedye, Study Chair*

## Site accrual

We're off to a great start with two patients recruited to the KEYPAD study in 2021 taking our accrual to 44/70. With only 26 patients remaining we thank all site staff for their ongoing support in helping us reach the target. Please continue to discuss the study at MDTs and encourage colleagues to refer any eligible patients if and when possible. Please don't hesitate to contact the KEYPAD team for any eligibility or study questions: [KEYPAD@ctc.usyd.edu.au](mailto:KEYPAD@ctc.usyd.edu.au)

Site name	Participants to Date
Northern Cancer Institute	1
Concord Repatriation General Hospital	7
St Vincent's Hospital Sydney	0
St George Hospital	7
Calvary Mater Newcastle	8
Peter MacCallum Cancer Center	1
Eastern Health / Box Hill	1
Monash Health (Monash Medical Centre Clayton of Monash Health)	1
Ballarat Oncology and Haematology Services	2
Royal Brisbane & Women's Hospital	4
The Townsville Hospital	1
ICON cancer Care Centre	1
Sunshine Coast University Hospital	5
Flinders Medical Centre	3
Fiona Stanley Hospital	2
<b>Grand Total</b>	<b>44</b>

## What is KEYPAD?

*Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial.*

## STUDY CHAIR

**A/Professor  
Craig Gedye**



## COVID-19 protocol deviations

Please continue to refer to the COVID-19 guidance document and report any protocol deviations as instructed. If a KEYPAD patient tests positive for COVID-19 please ensure prompt reporting to the CTC via email as well as on InForm. Any questions or assistance please contact the study team:

[KEYPAD@ctc.usyd.edu.au](mailto:KEYPAD@ctc.usyd.edu.au).

## Tissue blocks

1. Prior to registration, confirm availability of tissue block using the Tissue Availability Form (V3.1, 16-Dec-2019).
2. After registration, request block and ship to central lab as soon as possible. Please forward completed tissue log for our records.
3. If pathology decline to release block, DO NOT CUT SLIDES until requested by the KEYPAD team.

*KEYPAD is a collaboration  
between ANZUP and NHMRC  
Clinical Trials Centre.*



*This investigator initiated ANZUP  
study has been supported both  
financially and with study drug by  
MSD and Amgen.*



**MSD**




*ANZUP is supported by the  
Australian Government  
through Cancer Australia.*



**Australian Government  
Cancer Australia**



**18-20 JULY 2021**  
**ADELAIDE  
CONVENTION  
CENTRE**



## KEYPAD key contacts

- Clinical trial operations, CTC E: [keypad@ctc.usyd.edu.au](mailto:keypad@ctc.usyd.edu.au)
- Coordinating PI: Craig Gedye E: [craig.gedye@newcastle.edu.au](mailto:craig.gedye@newcastle.edu.au)
- Sponsor queries (payments, contracts) E: [trials@anzup.org.au](mailto:trials@anzup.org.au)
- Trial pages: <https://www.anzup.org.au/content.aspx?page=keypad>